Over the past decade, “incremental innovation” (pharmaceutical innovations that improve on existing drug therapies) has accounted for 70% of the new drugs approved in the US and a substantial portion of the industry’s revenues. However, concerns that reformulated drugs are being used to delay or preclude generic competition have given rise to a number of high-profile antitrust suits, including cases concerning the drugs BuSpar, Nexium/Prilosec, and DDAVP, among others. Click here to download a PDF of this article:
New research on the use of conjoint surveys with market simulation analysis for damages estimation in consumer protection class action litigation
Market simulations that we have seen used in consumer protection class action litigation apply what is known as the static Nash Bertrand model of competition...